acc1801 |
GSTP1 |
phosphorylation |
Tyr7 |
human |
Glioblastoma |
U87-MG |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1802 |
GSTP1 |
phosphorylation |
Tyr198 |
human |
Breast Cancer |
SUM 149 |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1803 |
GSTP1 |
phosphorylation |
Tyr198 |
human |
Breast Cancer |
SUM 149 |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1804 |
GSTP1 |
phosphorylation |
Tyr198 |
human |
Glioma |
MGR3 |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1805 |
GSTP1 |
phosphorylation |
Tyr198 |
human |
Glioma |
U87-MG |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1806 |
p65 |
acetylation |
Lys310 |
human |
Pancreas Cancer |
PANC-1 |
ICB |
Enhancing |
4.5 |
35265200
|
acc1807 |
p65 |
acetylation |
Lys310 |
human |
Pancreas Cancer |
MIA PaCa-2 |
ICB |
Enhancing |
4.5 |
35265200
|
acc1808 |
MtCK1 |
phosphorylation |
Tyr153 |
human |
Breast Cancer |
SK-BR-3 |
Lapatinib |
Impairing |
5.0 |
30174304
|
acc1809 |
MtCK1 |
phosphorylation |
Tyr153 |
human |
Breast Cancer |
BT474(trastuzumab-resistant) |
Lapatinib |
Impairing |
5.0 |
30174304
|
acc1810 |
ERK1 |
phosphorylation |
Thr202 |
human |
Endometrial Cancer |
Ishikawa |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1811 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Endometrial Cancer |
Ishikawa |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1812 |
ERK2 |
phosphorylation |
Thr185 |
human |
Endometrial Cancer |
Ishikawa |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1813 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Endometrial Cancer |
Ishikawa |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1814 |
ERK1 |
phosphorylation |
Thr202 |
human |
Endometrial Cancer |
HEC-1A |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1815 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Endometrial Cancer |
HEC-1A |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1816 |
ERK2 |
phosphorylation |
Thr185 |
human |
Endometrial Cancer |
HEC-1A |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1817 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Endometrial Cancer |
HEC-1A |
Trastuzumab |
Impairing |
5.0 |
12763221
|
acc1818 |
HER2 |
phosphorylation |
Tyr1221 |
human |
Breast Cancer |
MDA-MB-453m1 |
SUCI02 |
Associated |
4.0 |
12917021
|
acc1819 |
HER2 |
phosphorylation |
Tyr1222 |
human |
Breast Cancer |
MDA-MB-453m1 |
SUCI02 |
Associated |
4.0 |
12917021
|
acc1820 |
HER2 |
phosphorylation |
Tyr |
human |
Breast Cancer |
MDA-MB-231 |
Emodin |
Associated |
4.0 |
10037184
|
acc1821 |
HER2 |
phosphorylation |
Tyr |
human |
Breast Cancer |
MDA-MB-231 |
Paclitaxel |
Impairing |
5.0 |
10037184
|
acc1822 |
HER2 |
phosphorylation |
Tyr |
human |
Breast Cancer |
MDA-MB-361 |
Emodin |
Associated |
4.0 |
10037184
|
acc1823 |
HER2 |
phosphorylation |
Tyr |
human |
Breast Cancer |
MDA-MB-361 |
Paclitaxel |
Impairing |
5.0 |
10037184
|
acc1824 |
histone H4 |
acetylation |
Lys5 |
human |
Prostate Cancer |
C4-2 |
Enzalutamide |
Impairing |
4.5 |
34323404
|
acc1825 |
histone H4 |
acetylation |
Lys5 |
human |
Prostate Cancer |
22Rv1 |
Enzalutamide |
Impairing |
4.5 |
34323404
|
acc1826 |
histone H4 |
acetylation |
Lys5 |
human |
Prostate Cancer |
LNCaP |
Enzalutamide |
Impairing |
4.5 |
34323404
|
acc1827 |
histone H3 |
methylation |
Lys27 |
human |
Leukemia |
HL-60 |
ATRA |
Associated |
3.0 |
19578722
|
acc1828 |
histone H4 |
acetylation |
unclear |
human |
Leukemia |
HL-60 |
ATRA |
Associated |
3.0 |
19578722
|
acc1829 |
IDO |
acetylation |
unclear |
human |
Nasopharyngeal Carcinoma |
CNE2 |
NaB |
Associated |
4.0 |
25854569
|
acc1830 |
IDO |
acetylation |
unclear |
human |
Nasopharyngeal Carcinoma |
CNE2 |
NaB |
Associated |
4.0 |
25854569
|
acc1831 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H358 |
Gefitinib |
Impairing |
5.0 |
24374738
|
acc1832 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H322 |
Gefitinib |
Impairing |
5.0 |
24374738
|
acc1833 |
Ku70 |
acetylation |
unclear |
human |
Lung Cancer |
H358 |
Gefitinib |
Enhancing |
5.0 |
24374738
|
acc1834 |
Ku70 |
acetylation |
unclear |
human |
Lung Cancer |
H322 |
Gefitinib |
Enhancing |
5.0 |
24374738
|
acc1835 |
NF-kappaB's RelA |
acetylation |
Lys310 |
human |
Breast Cancer |
MDA-MB-231 |
13a |
Associated |
4.0 |
34378541
|
acc1836 |
p53 |
acetylation |
Lys382 |
human |
Glioblastoma |
U251 |
DWP0016 |
Associated |
4.0 |
23297003
|
acc1837 |
p53 |
acetylation |
Lys370 |
human |
Colorectal Cancer |
HCT116 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1838 |
p53 |
acetylation |
Lys372 |
human |
Colorectal Cancer |
HCT116 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1839 |
p53 |
acetylation |
Lys370 |
human |
Breast Cancer |
MCF7 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1840 |
p53 |
acetylation |
Lys372 |
human |
Breast Cancer |
MCF7 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1841 |
p53 |
acetylation |
Lys373 |
human |
Breast Cancer |
MCF7 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1842 |
p53 |
acetylation |
Lys381 |
human |
Breast Cancer |
MCF7 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1843 |
p53 |
acetylation |
Lys382 |
human |
Breast Cancer |
MCF7 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1844 |
p53 |
acetylation |
Lys373 |
human |
Colorectal Cancer |
HCT116 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1845 |
p53 |
acetylation |
Lys381 |
human |
Colorectal Cancer |
HCT116 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1846 |
p53 |
acetylation |
Lys382 |
human |
Colorectal Cancer |
HCT116 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1847 |
p53 |
acetylation |
Lys370 |
human |
Lung Cancer |
A549 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1848 |
p53 |
acetylation |
Lys372 |
human |
Lung Cancer |
A549 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1849 |
p53 |
acetylation |
Lys373 |
human |
Lung Cancer |
A549 |
MS-275 |
Associated |
4.0 |
36257192
|
acc1850 |
p53 |
acetylation |
Lys381 |
human |
Lung Cancer |
A549 |
MS-275 |
Associated |
4.0 |
36257192
|